[go: up one dir, main page]

UA102867C2 - Антитіла до cxcr4 та їх застосування у лікуванні раку - Google Patents

Антитіла до cxcr4 та їх застосування у лікуванні раку

Info

Publication number
UA102867C2
UA102867C2 UAA201105412A UAA201105412A UA102867C2 UA 102867 C2 UA102867 C2 UA 102867C2 UA A201105412 A UAA201105412 A UA A201105412A UA A201105412 A UAA201105412 A UA A201105412A UA 102867 C2 UA102867 C2 UA 102867C2
Authority
UA
Ukraine
Prior art keywords
antibodies
cancer
treatment
cxcr4
cxcr4 antibodies
Prior art date
Application number
UAA201105412A
Other languages
English (en)
Russian (ru)
Inventor
Крістін Клінгер-Амур
Веронік Греньє-Коссанель
Original Assignee
Пьєр Фабр Медікамент
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пьєр Фабр Медікамент filed Critical Пьєр Фабр Медікамент
Publication of UA102867C2 publication Critical patent/UA102867C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Винахід стосується нового ізольованого антитіла або його похідного, або функціонального фрагмента, здатного зв'язуватися з CXCR4, а також викликати конформаційні зміни гомодимерів та/або гетеродимерів CXCR4, зокрема даний винахід стосується антитіл 414Н5 та 515Н7, специфічних для білка CXCR4, а також їх застосування для лікування раку і способу відбору таких антитіл.
UAA201105412A 2008-10-01 2009-10-01 Антитіла до cxcr4 та їх застосування у лікуванні раку UA102867C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13677208P 2008-10-01 2008-10-01
EP08305631A EP2172485A1 (en) 2008-10-01 2008-10-01 Novel anti CXCR4 antibodies and their use for the treatment of cancer
US17374309P 2009-04-29 2009-04-29
PCT/EP2009/062787 WO2010037831A1 (en) 2008-10-01 2009-10-01 Anti cxcr4 antibodies and their use for the treatment of cancer

Publications (1)

Publication Number Publication Date
UA102867C2 true UA102867C2 (uk) 2013-08-27

Family

ID=40361774

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201105412A UA102867C2 (uk) 2008-10-01 2009-10-01 Антитіла до cxcr4 та їх застосування у лікуванні раку

Country Status (28)

Country Link
US (4) US8557964B2 (uk)
EP (2) EP2172485A1 (uk)
JP (1) JP5723279B2 (uk)
KR (1) KR101671039B1 (uk)
CN (1) CN102209730B (uk)
AR (1) AR073748A1 (uk)
AU (1) AU2009299787B2 (uk)
BR (1) BRPI0920531A2 (uk)
CA (1) CA2738782C (uk)
CL (1) CL2011000730A1 (uk)
CY (1) CY1115572T1 (uk)
DK (1) DK2342233T3 (uk)
ES (1) ES2503732T3 (uk)
GE (1) GEP20146084B (uk)
HR (1) HRP20140899T1 (uk)
IL (1) IL212066A (uk)
MA (1) MA32928B1 (uk)
MX (1) MX2011003509A (uk)
NZ (1) NZ592363A (uk)
PL (1) PL2342233T3 (uk)
PT (1) PT2342233E (uk)
RS (1) RS53578B1 (uk)
RU (1) RU2573897C2 (uk)
SI (1) SI2342233T1 (uk)
TW (1) TWI469792B (uk)
UA (1) UA102867C2 (uk)
WO (1) WO2010037831A1 (uk)
ZA (1) ZA201102969B (uk)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
WO2012055980A1 (en) * 2010-10-27 2012-05-03 Pierre Fabre Medicament Antibodies for the treatment of hiv
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
AR087364A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
NL2010658C2 (en) * 2013-04-18 2014-10-21 Bosch Gmbh Robert Thermostat for a hvac.
TWI671317B (zh) * 2013-08-02 2019-09-11 輝瑞大藥廠 抗ｃｘｃｒ４抗體及抗體-藥物結合物
US10584354B2 (en) 2013-09-23 2020-03-10 Wilson Wolf Manufacturing Methods of genetically modifying animal cells
TWI740824B (zh) * 2015-04-27 2021-10-01 法商皮爾法伯製藥公司 新穎的ｉｇｆ－１ｒ抗體及其用於癌症診斷之用途（一）
CA2989144A1 (en) 2015-06-12 2016-12-15 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
WO2017079835A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
WO2017079833A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
US10973852B2 (en) 2016-01-25 2021-04-13 Nantcell, Inc. NK cells with altered CXCL12/CXCR4 signaling
JPWO2017203799A1 (ja) * 2016-05-25 2019-02-28 株式会社東芝 エネルギー管理装置、管理システム、消費電力監視方法及びプログラム
BR112018076281A2 (pt) 2016-06-20 2019-03-26 Kymab Limited imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
JP2020508697A (ja) * 2017-01-31 2020-03-26 エム・エス・エム・プロテイン・テクノロジーズ・インコーポレイテッド 抗ｃｘｃｒ４抗体
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN112513079A (zh) 2018-03-13 2021-03-16 拉巴斯大学医院生物医学研究基金会 用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体
CN110804100A (zh) * 2019-11-01 2020-02-18 中国人民解放军陆军特色医学中心 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN112521500B (zh) * 2020-12-25 2022-06-24 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及应用
CN112661845B (zh) * 2020-12-25 2022-06-21 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及其应用
WO2025049591A1 (en) * 2023-08-28 2025-03-06 Regeneron Pharmaceuticals, Inc. Anti-cxcr4 antibodies and uses thereof
CN118255888A (zh) * 2023-08-31 2024-06-28 恺佧生物科技(上海)有限公司 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6949243B1 (en) * 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
US9029097B2 (en) * 2005-02-16 2015-05-12 Universite De Montreal Biosensors for monitoring receptor-mediated G-protein activation
CA2597717C (en) * 2005-02-18 2014-10-21 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
AU2009246683A1 (en) * 2008-05-14 2009-11-19 Eli Lilly And Company Anti-CXCR4 antibodies

Also Published As

Publication number Publication date
AR073748A1 (es) 2010-12-01
EP2342233B1 (en) 2014-06-25
NZ592363A (en) 2012-08-31
BRPI0920531A2 (pt) 2021-02-23
RU2573897C2 (ru) 2016-01-27
EP2342233A1 (en) 2011-07-13
IL212066A0 (en) 2011-06-30
CA2738782C (en) 2017-11-28
US20140050661A1 (en) 2014-02-20
US20110020218A1 (en) 2011-01-27
TW201018483A (en) 2010-05-16
US20110287451A1 (en) 2011-11-24
AU2009299787A2 (en) 2011-06-02
CN102209730B (zh) 2014-11-05
SI2342233T1 (sl) 2014-10-30
TWI469792B (zh) 2015-01-21
KR20110081229A (ko) 2011-07-13
ZA201102969B (en) 2011-12-28
US20110294156A1 (en) 2011-12-01
ES2503732T3 (es) 2014-10-07
AU2009299787A1 (en) 2010-04-08
GEP20146084B (en) 2014-05-13
HRP20140899T1 (hr) 2014-11-07
IL212066A (en) 2015-05-31
JP2012504401A (ja) 2012-02-23
CL2011000730A1 (es) 2012-02-03
PT2342233E (pt) 2014-10-03
CA2738782A1 (en) 2010-04-08
KR101671039B1 (ko) 2016-11-01
DK2342233T3 (da) 2014-09-29
US9388248B2 (en) 2016-07-12
AU2009299787B2 (en) 2015-06-18
RS53578B1 (sr) 2015-02-27
CN102209730A (zh) 2011-10-05
HK1163119A1 (en) 2012-09-07
US8557964B2 (en) 2013-10-15
MA32928B1 (fr) 2012-01-02
EP2172485A1 (en) 2010-04-07
JP5723279B2 (ja) 2015-05-27
RU2011115559A (ru) 2012-11-10
PL2342233T3 (pl) 2014-11-28
CY1115572T1 (el) 2017-01-04
MX2011003509A (es) 2011-05-02
WO2010037831A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
TN2011000534A1 (en) Anti cxcr4 antibodies for the treatment of hiv
NZ754051A (en) Novel antibodies and uses thereof
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
UA99602C2 (uk) Антитіло, яке специфiчно зв'язується з jam-a, здатне інгібувати проліферацію пухлинних клітин
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
TW200740844A (en) Novel MAdCAM antibodies
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
MX345092B (es) Anticuerpos anti-tau humanos,.
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
MX354481B (es) Anticuerpos dkk1 y métodos de uso.
MX2013004897A (es) Anticuerpos y composiciones anti-her3.
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
WO2008027739A3 (en) Antibodies to ntb-a
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
WO2009051957A3 (en) Antibodies to irem-1
PH12012501743A1 (en) Antigen binding proteins specific for serum amyloid p component
WO2012075342A3 (en) Anti-bradykinin b2 receptor (bkb2r) monoclonal antibody
MX2022005718A (es) Anticuerpos tmem219 y usos terapeuticos de los mismos.
MX2013004710A (es) Anticuerpos para el tratamiento de vih.
TN2011000150A1 (en) Anti cxcr4 antibodies and their use for the treatment of cancer
TH149197A (th) แอนตี้ cxcr4 แอนตี้บอดี้ที่ถูกสร้างโดยมนุษย์สำหรับการรักษาของมะเร็ง
CO6390002A2 (es) Anticuerpos anti-cxcr4 nuevos y su utilizacion para el tratamiento del cancer